HilleVax Inc

HilleVax, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was founded by Dr. Maurice Hilleman and Dr. Tadataka Yamada on 3rd March, 2020 and is headquartered in Boston, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

NEW YORK CITY, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites HLVX Investors To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc

NEW YORK CITY, NY / ACCESSWIRE / July 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Stockholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HLVX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by HilleVax, Inc.

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

HLVX Investors Are Welcomed By The Schall Law Firm To Join Its Inquiry Into Suspected Securities Fraud At HilleVax Inc

NEW YORK CITY, NY / ACCESSWIRE / July 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Stockholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HilleVax, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - HLVX

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc

NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages HLVX Stakeholders To Join Its Probe Into Suspected Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Into Alleged Securities Fraud At HilleVax Inc

NEW YORK CITY, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders Of HLVX Are Urged To Join The Schall Law Firm's Investigation Of Securities Fraud At HilleVax Inc

HilleVax (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround

NEW YORK CITY, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

HLVX Stakeholders Are Encouraged To Participate In The Securities Fraud Investigation Of HilleVax Inc Led By The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm!

HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

HLVX Stakeholders Are Invited To Join The HilleVax Inc Securities Fraud Probe Conducted By The Schall Law Firm

HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.

HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday.

Gold Falls Over 1%; HilleVax Shares Plunge

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In HLVX Can Participate In The Securities Fraud Investigation Of HilleVax Inc With The Schall Law Firm

HilleVax (NASDAQ: HLVX ) stock is falling hard on Monday following the release of topline data from its Phase 2b clinical trial of HIL-214 in infants. This clinical trial studied the efficacy, safety, and immunogenicity of HIL-214 as a norovirus vaccine for infants.

Why Is HilleVax (HLVX) Stock Down 87% Today?

LOS ANGELES--(BUSINESS WIRE)--HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm.

News for HilleVax Inc Stock (HLVX)